Emergency loan keeps biotech firm afloat – crucial to staying operational

The Biotech company Acesion Pharma has taken up a Covid-19 emergency loan worth DKK 20m from the Danish Growth Fund to keep the engines running. An important phase II study has been postponed by at least six months, according to the firm's executive chairman.

Photo: Novo Holdings / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles